CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: A Hoosier oncology group phase II trial

A. Sandler, C. Blanke, F. Monaco, M. A. Carey, R. Ansari, B. Fisher, C. H. Spiridonidis, L. Einhorn, C. Nichols

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: A Hoosier oncology group phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences